"A multispecialty community and teaching hospital providing quality health care services to the residents of Greater New Britain, Connecticut."

During the past decade, The Hospital of Central Connecticut conducted 51 clinical trials. In the 10-year time frame, 51 clinical trials started and 112 clinical trials were completed, i.e. on average, 219.6% percent of trials that started reached the finish line to date. In the past 5 years, 15 clinical trials started and 54 clinical trials were completed. i.e. 360% of trials that started reached the finish line.

Out of the total clinical trials conducted in "The Hospital of Central Connecticut" #1 sponsor was "National Cancer Institute (NCI)" with 81 trials, followed by "Gynecologic Oncology Group" with 32 trials sponsored, "SWOG Cancer Research Network" with 15 trials sponsored, "GOG Foundation" with 10 trials sponsored and "Alliance for Clinical Trials in Oncology" with 10 trials sponsored. Other sponsors include 35 different institutions and companies that sponsored additional 28 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "The Hospital of Central Connecticut" #1 collaborator was "National Cancer Institute (NCI)" with 77 trials as a collaborator, "NRG Oncology" with 48 trials as a collaborator, "Canadian Cancer Trials Group" with 5 trials as a collaborator, "Cancer and Leukemia Group B" with 4 trials as a collaborator and "Eastern Cooperative Oncology Group" with 4 trials as a collaborator. Other collaborators include 29 different institutions and companies that were collaborators in the rest 23 trials.

According to Clinical.Site data, the most researched conditions in "The Hospital of Central Connecticut" are "Recurrent Ovarian Carcinoma" (20 trials), "Recurrent Fallopian Tube Carcinoma" (18 trials), "Recurrent Primary Peritoneal Carcinoma" (17 trials), "Endometrial Clear Cell Adenocarcinoma" (12 trials) and "Cervical Adenocarcinoma" (11 trials). Many other conditions were trialed in "The Hospital of Central Connecticut" in a lesser frequency.

Most popular intervention types in "The Hospital of Central Connecticut" are "Drug" (143 trials), "Other" (121 trials), "Biological" (65 trials), "Procedure" (34 trials) and "Radiation" (28 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (80 trials), "Quality-of-Life Assessment" (47 trials), "Paclitaxel" (35 trials), "Carboplatin" (25 trials) and "Bevacizumab" (24 trials). Other intervention names were less common.

The vast majority of trials in "The Hospital of Central Connecticut" are 96 trials for "Female" genders, 83 trials for "All" genders and 4 trials for "Male" genders.

Currently, there are NaN active trials in "The Hospital of Central Connecticut". undefined are not yet recruiting, 15 are recruiting, 67 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 82 completed trials in The Hospital of Central Connecticut, undefined suspended trials, and 12 terminated clinical trials to date.

Out of the total trials that were conducted in The Hospital of Central Connecticut, 9 "Phase 1" clinical trials were conducted, 83 "Phase 2" clinical trials and 82 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 10 trials that are defined as “Not Applicable".

The Hospital of Central Connecticut has several departments that took part in Clinical trials: "George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus" - 53 trials, "Hartford HealthCare Cancer Institute at The Hospital of Central Connecticut" - 4 trials